-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Initiates Coverage On BridgeBio Oncology with Buy Rating, Announces Price Target of $23

Benzinga·02/11/2026 15:06:44
Listen to the news
Stifel analyst Laura Prendergast initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Buy rating and announces Price Target of $23.